<DOC>
	<DOCNO>NCT01502423</DOCNO>
	<brief_summary>This study compare injection site pain level current Humira® formulation versus new formulation Humira patient Rheumatoid Arthritis ( RA ) , either currently stable dose ( minimum six consecutive dos ) on-label Humira biological naïve prescribe on-label Humira treatment Rheumatoid Arthritis . The study conduct three country , Australia ( 3 site ) , Canada ( 2 site ) , Germany ( 2 site ) .</brief_summary>
	<brief_title>A Crossover Study Safety Tolerability Two Formulations Adalimumab</brief_title>
	<detailed_description>61 participant randomize , 60 receive least one dose study drug . One participant , randomize New formulation adalimumab/Current formulation adalimumab arm study , discontinue study never receive study drug .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male female subject age 18 year old , require Humira 40 mg SC every week ( eow ) every week ( ew ) treatment rheumatoid arthritis , accordance local Humira label . Subject must current , onlabel user Humira rate his/her average Humira injection site relate pain least 3 cm pain Visual Analogue Scale least 6 consecutive dos Humira prior Screening , biologic naïve subject require initiation onlabel treatment Humira . Subject diagnosis rheumatoid arthritis ( RA ) define 1987 revised ACR classification criterion ACR/EULAR 2010 criterion , Female subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy and/or hysterectomy ) , practice least one method birth control throughout study least 70 day last dose study drug . All female subject childbearing potential must negative test pregnancy serum sample Screening prior study drug dose urine sample obtain Visit 1 . Subject treated investigational drug chemical biologic nature within minimum 30 day 5 halflives ( whichever longer ) drug prior Visit 1 . Any infection ( ) require treatment intravenous ( IV ) antiinfectives within 30 day prior Visit 1 oral antiinfectives within 14 day prior Visit 1 . Prior exposure natalizumab ( Tysabri® ) efalizumab ( Raptiva® ) . Known hypersensitivity adalimumab excipients . History demyelinate disease ( include myelitis ) neurologic symptom suggestive demyelinate disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>On label Humira user</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Pain</keyword>
</DOC>